Osteoporosis Treatment Overview

Osteoporosis is a condition defined by decreased bone density and increased fracture risk, affecting millions worldwide—especially postmenopausal women and older men. Modern treatments focus on reducing fracture risk and strengthening bones through medication, lifestyle modifications, and addressing secondary causes.

First-Line Osteoporosis Medications

Bisphosphonates remain the primary first-line therapy for most women and men with osteoporosis. Common options include:

• Alendronate (Fosamax): oral, weekly

• Risedronate (Actonel, Atelvia): oral, weekly/monthly

• Ibandronate (Boniva): oral, monthly or quarterly IV infusion

• Zoledronic acid (Reclast/Aclasta): annual IV infusion

These medications slow bone breakdown and reduce hip and spine fracture risk significantly. Typically, treatment duration is three to five years, sometimes followed by a “drug holiday” since bisphosphonates can continue to protect bone after stopping.

Common bisphosphonate side effects include stomach upset and heartburn with oral forms. IV forms avoid stomach issues but may cause flu-like symptoms, especially after the first treatment. Rare but serious side effects are atypical femoral fractures and osteonecrosis of the jaw.

Osteoporosis weakens bones, increasing risk of fractures—know your treatment options

Alternatives to Bisphosphonates

If you cannot tolerate bisphosphonates or have specific contraindications (e.g., kidney problems), several other medicines are available:

• Denosumab (Prolia): Monoclonal antibody injection given every 6 months under the skin. Effective at stopping bone loss, reducing vertebral and non-vertebral fractures. Must be continued without interruption, or fracture risk will rise sharply.

  • Cost: List price about $1,875 per injection every six months in the US; retail pharmacy prices may start at $1,734.40 but vary with insurance and location.

• Raloxifene (Evista): A selective estrogen receptor modulator (SERM). Used especially for postmenopausal women; also lowers breast cancer risk but may raise blood clot risk.

• Hormone Therapy: Generally reserved for younger postmenopausal women who can’t take other options, and only for a defined period.

Bone-Building (Anabolic) Medications

For people at highest fracture risk or with very low bone density/failure on other treatments, bone-building treatments (“anabolics”) are considered:

• Teriparatide (Forteo) and Abaloparatide (Tymlos): Daily self-injection for up to two years. Build new bone, decrease fracture risk substantially.

  • Prices in 2025: In India, teriparatide injections range from ₹3,000–₹12,000 per dose (~$36–$145 USD); costs in the US or Europe are significantly higher—consult local providers for up-to-date numbers.

• Romosozumab (Evenity): Dual-action medicine (builds bone and reduces resorption), given as two injections monthly for up to 12 months. Used for very high-risk patients; more effective than antiresorptives for vertebral fractures but requires follow-up with antiresorptive treatment.

• Zoledronic acid infusion: Typically a once-yearly IV treatment.

Additional Osteoporosis Treatments

• Calcitonin: Less effective than other medications, used less often in modern practice.

• Calcium and Vitamin D: Support medication efficacy; recommended for all at-risk adults.

Lifestyle and Non-Pharmacologic Strategies

• Exercise: Weight-bearing and resistance activities to strengthen bone and improve balance.

• Nutrition: Adequate calcium and vitamin D intake (prefer dietary calcium).

• Fall Prevention: Assess home safety and consider balance training.

Monitoring, Holidays, and Special Scenarios

• Treatments are reviewed regularly (every 1–2 years) with bone density tests.

• A “drug holiday” from bisphosphonates may be advised after 3–5 years for those at low-moderate risk.

• Denosumab must NOT be stopped suddenly—transition planning is essential to avoid rebound fractures.